Sponsor:
Jazz Pharmaceuticals
Code:
NCT04899947
Conditions
Narcolepsy
Eligibility Criteria
Sex: All
Age: 0 - 17
Healthy Volunteers: Not accepted
Brief summary:
Conditions
Narcolepsy
Study ID
NCT04899947
Start date
Oct 10, 2020
Status verified date
Aug, 2024
Completion date
Oct 1, 2024
Anticipated
Primary completion date
Oct 1, 2024
Anticipated
Eligibility Criteria
Sex: All
Age: 0 - 17
Healthy Volunteers: Not accepted
Enrollment
500 participants
Anticipated
Primary outcome measure
Central contacts
Locations
University of Arizona
Recruiting
Tucson, Arizona, United States, 85719
Arkansas Children's Research Institute
Recruiting
Little Rock, Arkansas, United States, 72202
Stanford University
Recruiting
Redwood City, California, United States, 94063
University of California San Diego
Recruiting
San Diego, California, United States, 92093
University of South Florida
Recruiting
Tampa, Florida, United States, 33620
Boston Children's Hospital
Recruiting
Boston, Massachusetts, United States, 02115
St. Luke's Hospital
Recruiting
Chesterfield, Missouri, United States, 63017
Children's Mercy Hospital
Recruiting
Kansas City, Missouri, United States, 64108
Northwell Health
Recruiting
Manhasset, New York, United States, 11030
Cincinnati Children's Hospital Medical Center
Recruiting
Cincinnati, Ohio, United States, 45229
University Hospitals Cleveland Medical Centre (UHCMC)
Recruiting
Cleveland, Ohio, United States, 44106
Ohio Sleep Medicine Institute
Recruiting
Dublin, Ohio, United States, 43017
Geisinger
Recruiting
Danville, Pennsylvania, United States, 17822
Children's Hospital of Philadelphia
Recruiting
Philadelphia, Pennsylvania, United States, 19104
Texas Children's Hospital (Baylor College of Medicine)
Recruiting
Houston, Texas, United States, 77030
Children's Hospital of the King's Daughters
Recruiting
Norfolk, Virginia, United States, 23507
Sponsor
Jazz Pharmaceuticals
Last update posted
Aug 15, 2024
Last verified
Aug, 2024
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Jazz Pharmaceuticals on 2024-08-15.